Culver City, Calif.-based NantHealth and Asia Genomics have entered into an agreement to offer NantHealth's GPS Cancer tests to physicians throughout Southeast Asia.
GPS Cancer is a proteogenomic molecular test that helps oncologists guide treatment strategies. It sequences the whole genome of more than 20,000 genes and three billion base pairs, matching against the patient's normal DNA to help inform personalized treatment strategies.
Asia Genomics, a provider and distributor of molecular testing services in Southeast Asia, will offer the GPS Cancer tool in Singapore, Malaysia, Thailand, Vietnam and the Philippines.
More articles on data analytics & precision medicine:
Yale New Haven Health System integrates ActX Genomic Decision Support in Epic EHR
Wisconsin researchers awarded $5.3M for NIH All of Us program
Chicagoland hospital to offer genetic testing as part of an annual checkup